HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Milton Saute Benjamin Medalion Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Amital, A. Articles by Kramer, M. R. Search for Related Content PubMed Articles by Amital, A. Articles by Kramer, M. R. Related Collections Lung - other Lung - transplantation Pleura

Surfactant as salvage therapy in life threatening primary graft dysfunction in lung transplantation

^a Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
^b Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Received 7 May 2008; received in revised form 9 September 2008; accepted 17 September 2008.

^_* Corresponding author. Address: Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqwa 49100, Israel. Tel.: +972 3 9377221; fax: +972 3 9242091. (Email: kramerm{at}netvision.net.il).

Objective: Impaired surfactant activity may contribute to primary graft dysfunction after lung transplantation. We assessed the role of surfactant treatment in lung transplant recipients with severe life threatening primary lung graft dysfunction. Patients and methods: Five patients after lung transplantation: 4 after single-lung transplantation, for emphysema (n = 3) or idiopathic pulmonary fibrosis (n = 1), and 1 patient after double-lung transplantation for cystic fibrosis. All had severe life threatening primary graft dysfunction that failed to respond to conventional measures. Treatment consisted of bronchoscopic instillation of mammalian surfactant, 20–90 cc, at 3 (n = 1) or 7 days (n = 4) after transplantation. Results: There was a significant improvement in the ratio of partial arterial oxygen tension (PaO₂) to fractional concentration of oxygen in inspired gas (FIO₂), from a mean of 98.8 ± 21.7 to 236.8 ± 52.3 mmHg (p = 0.0006), within hours of treatment. All were eventually discharged home and showed a satisfactory FEV₁ (44–67% predicted) at the 6-month follow-up. All patients were still alive 6 months or more after transplantation. Conclusion: Surfactant treatment improves oxygenation and may be life saving in patients with primary lung graft dysfunction.

Key Words: Surfactant • Lung transplantation • Primary graft dysfunction